Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis
- Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe
- Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521